A Phase 3, Randomized, Placebo-controlled, Double-blind, Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Patients With Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (PH-COPD)
Phase of Trial: Phase III
Latest Information Update: 08 Nov 2019
Price : $35 *
At a glance
- Drugs Treprostinil (Primary)
- Indications Pulmonary hypertension
- Focus Registrational; Therapeutic Use
- Acronyms PERFECT
- Sponsors United Therapeutics Corporation
- 19 Jun 2019 Planned End Date changed from 1 Sep 2020 to 30 Sep 2020.
- 19 Jun 2019 Planned primary completion date changed from 1 Sep 2020 to 30 Sep 2020.
- 31 Aug 2018 Biomarkers information updated